Humacyte, Inc. Proceeds from Bank Debt
Humacyte, Inc. (HUMA) reported Proceeds from Bank Debt of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-24.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromBankDebt · last filed 2023-03-24
- Humacyte, Inc. proceeds from bank debt for the quarter ending 2022-12-31 was $0.00, a 100.00% decline year-over-year.
- Humacyte, Inc. proceeds from bank debt for the quarter ending 2022-09-30 was $0.00.
- Humacyte, Inc. proceeds from bank debt for the quarter ending 2022-06-30 was $0.00.
- Humacyte, Inc. proceeds from bank debt for the quarter ending 2022-03-31 was $0.00, a 100.00% decline year-over-year.
- Humacyte, Inc. proceeds from bank debt for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- Humacyte, Inc. proceeds from bank debt for fiscal 2021 was $29.66M.
- Humacyte, Inc. proceeds from bank debt for fiscal 2020 was $0.00.
| Period end | Proceeds from Bank Debt 3 month | Proceeds from Bank Debt 6 month | Proceeds from Bank Debt 9 month | Proceeds from Bank Debt 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-24 | $0.00 derived: sum of 2 quarters · filed 2023-03-24 | $0.00 derived: sum of 3 quarters · filed 2023-03-24 | $0.00 10-K · filed 2023-03-24 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $0.00 derived: sum of 2 quarters · filed 2022-11-10 | $0.00 10-Q · filed 2022-11-10 | $10.00M derived: sum of 4 quarters · filed 2023-03-24 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | $0.00 10-Q · filed 2022-08-12 | $10.00M derived: sum of 3 quarters · filed 2023-03-24 | $10.00M derived: sum of 4 quarters · filed 2023-03-24 |
| 2022-03-31 | $0.00 10-Q · filed 2022-05-13 | $10.00M derived: sum of 2 quarters · filed 2023-03-24 | $10.00M derived: sum of 3 quarters · filed 2023-03-24 | $10.00M derived: sum of 4 quarters · filed 2023-03-24 |
| 2021-12-31 | $10.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-24 | $10.00M derived: sum of 2 quarters · filed 2023-03-24 | $10.00M derived: sum of 3 quarters · filed 2023-03-24 | $29.66M 10-K · filed 2023-03-24 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $0.00 derived: sum of 2 quarters · filed 2022-11-10 | $19.66M 10-Q · filed 2022-11-10 | |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | $19.66M 10-Q · filed 2022-08-12 | ||
| 2021-03-31 | $19.66M 10-Q · filed 2022-05-13 | |||
| 2020-12-31 | $0.00 10-K · filed 2022-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |